Clinical Trials · NCT01137695

Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus

UnknownPhase 3Pramlintide (Unclear)
Phase
Phase 3
Recruitment status
Unknown
Sponsor
Cheryl Rosenfeld, DO
Enrollment
40
Start date
May 2010
Locations
3 sites, United States
Primary endpoint
Glucose control
View Pramlintide compound reference